New Anticoagulants for Stroke Prevention in Atrial Fibrillation

Published Online: Tuesday, January 14, 2014
Follow Pharmacy_Times:
Christian Ruff, MD, MPH, of Harvard Medical School, gives an overview of the anticoagulants currently available for prevention of stroke in patients with atrial fibrillation.

Related Articles
Use of anticoagulants in atrial fibrillation patients remains unacceptably low, with some estimates showing that only half of patients receive anticoagulants as indicated by current treatment guidelines.
One of the most common questions from prescribers that I have answered in the past year concerns how to convert from 1 anticoagulant to anothe
Not every patient requires an aspirin a day.
Preliminary results of an ongoing post-marketing study examining Janssen Pharmaceuticals’ rivaroxaban (Xarelto) in patients with non-valvular atrial fibrillation (NVAF) indicate that the anti-clotting drug’s safety in real-world settings is consistent with the findings of previous phase 3 clinical trials.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$